Analysis update: I am experiencing the Tetris Effect but for NVivo. Everything is coding. All is relationships. I’m colour-coding the day’s news.
Absolutely. Also: still plagiarism at the end of the day.
Reckon it was the result of some AI trawling process or something? Or just a really brazen human?
Today I will mostly be analysing focus group transcripts. We got a really great mix of GPs, physios and the odd OT talking MSK pain in children & young people and the spread of opinion and experience has been fascinating.
Mornin’
I've been shocked at the reduction of utility over on the dead bird and all this stuff with Musk and politics has been awful. I'm glad to see people mobilising away from it all, and Bluesky seems like a very good fit for a replacement.
3rd FNP also from PhD: Barriers and facilitators in diagnosing axial spondyloarthritis: a qualitative study (DOI doi.org/10.1007/s002...). Shows communication issues, difficulty in diagnosing axSpA and systemic healthcare problems slowing up diagnosis of axSpA, among other things.
Introduction Diagnosis of axial spondyloarthritis (axSpA) is frequently delayed for years after symptom onset. However, little is known about patient and healthcare professional (HCP) perspectives on ...
2nd First Name Paper came from my PhD: Diagnostic delay in axial spondyloarthritis: a systematic review (DOI doi.org/10.1007/s100...). Showed diagnostic delay in axSpA ranging globally from 2-8 years, unaffected overall by gender or family history (I do discuss this because I know it sounds odd).
Identification of axial spondyloarthritis (axSpA) remains challenging, frequently resulting in a diagnostic delay for patients. Current benchmarks of delay are usually reported as mean data, which are...
My first First Name Paper was Mortality in Patients With Gout Treated With Allopurinol: A Systematic Review and Meta-Analysis (DOI doi.org/10.1002/acr....) which showed no effect of allopurinol on all-cause mortality in patients with gout.
Objective Urate-lowering therapy (predominantly allopurinol) is highly effective as a treatment for gout, but its wider long-term effects remain unclear. This systematic review and meta-analysis aim.....
Hi Bluesky! I'll kick things off with some shameless self-promotion: I'm on the @nihr.bsky.social@campainstudy.bsky.social study researching MSK pain in children and young people (CYP). Running interviews with CYP and guardians, and focus groups with HCPs and AHPs.